Poly Medicure Ltd
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
- Market Cap ₹ 21,056 Cr.
- Current Price ₹ 2,078
- High / Low ₹ 3,358 / 1,821
- Stock P/E 60.7
- Book Value ₹ 271
- Dividend Yield 0.14 %
- ROCE 20.0 %
- ROE 15.8 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 29.1% CAGR over last 5 years
Cons
- Stock is trading at 7.67 times its book value
- Working capital days have increased from 144 days to 313 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
312 | 373 | 393 | 439 | 507 | 586 | 646 | 746 | 879 | 1,068 | 1,306 | 1,602 | 1,618 | |
238 | 288 | 307 | 345 | 386 | 452 | 483 | 536 | 665 | 801 | 954 | 1,156 | 1,172 | |
Operating Profit | 74 | 85 | 86 | 94 | 122 | 134 | 162 | 210 | 214 | 266 | 353 | 445 | 446 |
OPM % | 24% | 23% | 22% | 21% | 24% | 23% | 25% | 28% | 24% | 25% | 27% | 28% | 28% |
11 | 28 | 8 | 13 | 14 | 16 | 19 | 19 | 39 | 36 | 57 | 90 | 114 | |
Interest | 9 | 10 | 10 | 8 | 11 | 13 | 20 | 10 | 5 | 10 | 13 | 11 | 11 |
Depreciation | 14 | 18 | 20 | 23 | 28 | 36 | 39 | 46 | 53 | 56 | 62 | 81 | 85 |
Profit before tax | 62 | 84 | 65 | 76 | 96 | 100 | 122 | 173 | 195 | 237 | 335 | 443 | 464 |
Tax % | 31% | 27% | 27% | 26% | 27% | 34% | 24% | 25% | 25% | 24% | 25% | 25% | |
43 | 61 | 47 | 56 | 70 | 66 | 92 | 130 | 146 | 179 | 252 | 331 | 347 | |
EPS in Rs | 4.88 | 6.92 | 5.36 | 6.37 | 7.96 | 7.51 | 10.47 | 13.51 | 15.23 | 18.66 | 26.23 | 32.70 | 34.24 |
Dividend Payout % | 20% | 18% | 28% | 39% | 25% | 27% | 19% | 19% | 16% | 16% | 11% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 20% |
3 Years: | 22% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 29% |
3 Years: | 36% |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 37% |
3 Years: | 40% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 16% |
3 Years: | 16% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Reserves | 122 | 170 | 202 | 225 | 290 | 336 | 385 | 906 | 1,029 | 1,186 | 1,410 | 2,694 |
67 | 76 | 79 | 97 | 127 | 150 | 194 | 126 | 111 | 137 | 165 | 172 | |
71 | 87 | 73 | 83 | 93 | 103 | 117 | 107 | 146 | 167 | 199 | 224 | |
Total Liabilities | 282 | 354 | 376 | 449 | 555 | 633 | 740 | 1,187 | 1,334 | 1,538 | 1,821 | 3,140 |
120 | 161 | 177 | 201 | 260 | 272 | 328 | 389 | 451 | 598 | 831 | 1,051 | |
CWIP | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 71 | 89 |
Investments | 6 | 6 | 6 | 6 | 18 | 42 | 58 | 385 | 384 | 181 | 221 | 1,127 |
137 | 178 | 180 | 222 | 258 | 300 | 330 | 392 | 456 | 681 | 699 | 873 | |
Total Assets | 282 | 354 | 376 | 449 | 555 | 633 | 740 | 1,187 | 1,334 | 1,538 | 1,821 | 3,140 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
65 | 63 | 62 | 55 | 76 | 113 | 127 | 116 | 126 | 197 | 256 | 237 | |
-58 | -57 | -30 | -54 | -87 | -104 | -106 | -434 | -89 | -189 | -237 | -1,191 | |
6 | -9 | -31 | -1 | 14 | -10 | -22 | 319 | -40 | -8 | -17 | 953 | |
Net Cash Flow | 13 | -2 | 1 | 0 | 3 | -1 | -1 | 1 | -2 | -0 | 2 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 53 | 58 | 75 | 79 | 81 | 77 | 68 | 73 | 80 | 76 | 72 | 78 |
Inventory Days | 140 | 146 | 105 | 193 | 207 | 138 | 241 | 202 | 210 | 222 | 194 | 172 |
Days Payable | 102 | 103 | 77 | 136 | 130 | 93 | 144 | 104 | 109 | 95 | 89 | 53 |
Cash Conversion Cycle | 91 | 101 | 103 | 136 | 157 | 123 | 165 | 171 | 181 | 203 | 177 | 196 |
Working Capital Days | 19 | 24 | 36 | 58 | 74 | 58 | 45 | 73 | 80 | 65 | 52 | 313 |
ROCE % | 33% | 30% | 26% | 25% | 26% | 23% | 25% | 21% | 16% | 19% | 22% | 20% |
Documents
Announcements
-
Investors/Analyst Call On Thursday 28Th August, 2025
1d - Virtual one-on-one investor meeting with WhiteOak on 28 Aug 2025.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
20 Aug - NCLT approved Poly Medicure's INR 33.15 Crore plan to acquire 100% of Himalayan Mineral Waters.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 14 Aug
-
Statement Of Deviation Or Variation In The Use Of Proceeds Of Equity Shares Issued Through QIP For The Quarter Ended June 30, 2025 As Per Regulation 32 Of The SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015
14 Aug - Poly Medicure reports no deviation in utilization of Rs 999.9998 crore QIP proceeds for June 2025 quarter.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Aug - CRISIL report confirms Poly Medicure's QIP proceeds utilized as per disclosed objects, no deviations noted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024TranscriptPPTREC
-
Sep 2024TranscriptNotesPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
Product Portfolio
It is a medical devices company with a product portfolio comprised of 200+ SKUs of medical devices across 12 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. [1]